Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.
Age 18 to 80 years. [+4]
Received any neoadjuvant therapy prior to surgery. [+4]